
    
      Patients with a history of paroxysmal atrial fibrillation, with or without a dual chamber
      pacemaker and who meet all study criteria, will be randomized to receive either a placebo, or
      simvastatin 40 mg, daily for 6 months.

      Liver enzymes are drawn at randomization and 3 months. CRP and oxidative stress products are
      drawn at randomization, weekly for the first month and then monthly for 5 months.

      Patients transmit their rhythm, twice daily for 5 consecutive days at randomization, then 5
      consecutive days monthly for 6 months.

      Clinic visits are required at randomization, 3 months and 6 months.
    
  